Detalles de la búsqueda
1.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
ESMO Open
; 5(1)2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31958290
Resultados
1 -
1
de 1
1
Próxima >
>>